<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288404</url>
  </required_header>
  <id_info>
    <org_study_id>055217</org_study_id>
    <nct_id>NCT01288404</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium</brief_title>
  <official_title>A Pilot Study of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization
      in pterygium, preventing or retarding the progression of recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Impending recurrent pterygium

        2. Anti-VEGF therapy

             -  Bevacizumab

             -  Subconjunctival injection

             -  Suppress neovascularization
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of impending recurrent pterygium</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog scales</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pterygium of the Conjunctiva and Cornea</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical 0.1% fluorometholone eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 1.25 mg/0.05mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 2.5 mg/0.1mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bevacizumab 3.75 mg/0.15mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorometholone</intervention_name>
    <description>topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>FML eye drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>subconjunctival bevacizumab 1.25 mg/0.05mL</description>
    <arm_group_label>Bevacizumab group 1</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>subconjunctival bevacizumab 2.5 mg/0.1mL</description>
    <arm_group_label>Bevacizumab group 2</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>subconjunctival bevacizumab 3.75 mg/0.15mL</description>
    <arm_group_label>bevacizumab group 3</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Impending recurrent pterygium developed within 6 months following pterygium surgery
             either simple excision or excision with grafting.

          2. Failure of conventional topical anti-inflammatory therapy for impending recurrent
             pterygium which was defined by the progression of fibrovascular tissue over the
             excised area despite receiving treatment.

          3. No history of any adjunctive treatment such as MMC, 5-FU, periocular injection of
             corticosteroids and beta radiation.

          4. No other ocular surface pathologies or coexisting ocular diseases.

          5. No other ocular surgeries within the previous 6 months.

          6. No history of allergy to the medications used in this study.

          7. Good compliance with the study regimen and availability for the duration of the entire
             study period.

        Exclusion Criteria:

          1. Platelet disorders

          2. Hypertension

          3. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaevalin Lekhanont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramathibodi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>February 1, 2011</last_update_submitted>
  <last_update_submitted_qc>February 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kaevalin Lekhanont</name_title>
    <organization>Ramathibodi Hospital</organization>
  </responsible_party>
  <keyword>Bevacizumab, impending recurrent pterygium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Fluorometholone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

